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Abstract
Objective: To test associations of pre-pregnancy BMI (BMI), gestational weight gain (GWG), 
oral glucose challenge test (OGCT) results, and post-partum weight loss (PPWL) as predictors of 
breastmilk leptin, insulin and adiponectin concentrations, and whether these relationships vary 
over time.
Methods: Milk was collected at 1- and 3 months from 135 exclusively breastfeeding women 
from the longitudinal Mothers and Infants Linked for Healthy Growth (MILk) study. Hormones 
were assayed in skimmed samples using ELISA. Mixed effects linear regression models were 
employed to assess main effects and effect-by-time interactions on hormone concentrations.
Results: In adjusted models, BMI was positively associated with milk leptin (p<0.001) and 
insulin (p=0.03), and negatively associated with milk adiponectin (p=0.02); however, the 
association with insulin was stronger and with adiponectin was weaker at 3-months than at 1-
month (time interaction p= 0.017 for insulin and p= 0.045 for adiponectin). GWG was positively 
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and PPWL was negatively associated with milk leptin (both p<0.001) independent of BMI. OGCT 
was not associated with these milk hormone concentrations.
Conclusion: Maternal weight status before, during, and after pregnancy contributes to inter-
individual variation in human milk composition. Continuing work will assess the role of these and 
other milk bioactive factors in altering infant metabolic outcomes.
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Introduction
Mothers’ milk is the gold standard for human infant nutrition, and breastfeeding exclusively 
to six months is strongly recommended by the American Academy of Pediatrics,1 American 
College of Obstetrics and Gynecologists, and World Health Organization.2 There is, 
however, evidence that human milk exhibits substantial individual variation in the 
concentration of appetite-regulating hormones, cytokine levels, fatty acid profiles, and other 
factors3,4 As reviewed by Ellsworth et al.,5 animal models provide intriguing evidence that 
maternal obesity may alter milk leptin, insulin, and other bioactive elements, which in turn 
are associated with diabetes, obesity, and hepatic steatosis in the adulthood offspring.5–7 As 
animal models do not always translate well into human studies, due to species differences in 
growth rate, mammary gland physiology, and critical windows of development5, more 
human research is needed to test the “lactational programming” hypothesis; that is, that 
variation in levels of hormones, cytokines and other bioactive compounds present in 
breastmilk may have sustained effects on offspring’s appetite and metabolic rate. Although 
25% of women in the United Stated have BMI in the obese range prior to pregnancy, 8 
increasing the risk of obesity in the offspring by 2-3 fold.9,10, the role of human milk 
composition in the transmission of obesity risk from mother to child has only recently been 
examined as a potential mechanism.
In line with this hypothesis, we and others have demonstrated positive associations between 
milk leptin levels and maternal BMI,11–13 but findings on the relationship of maternal BMI 
to milk insulin11,12,14,15 and adiponectin13,14,16–19 are less inconsistent. One factor that may 
explain disparate findings is that while milk composition is known to change over the course 
of lactation, ,with a general finding of declines in milk peptides over lactation,20,21 the 
current literature is characterized by within- and between-study heterogeneity in the timing 
of milk sample collection for analysis.16,19,22 Further, studies of milk hormone variation to 
date have not taken account of maternal metabolic status at different critical developmental 
windows. Growing evidence suggests that fetal, infant, and childhood adiposity and obesity 
risk are modified by pregnancy glucose dysregulation, gestational weight gain (GWG), and 
post-partum weight loss (PPWL), independent of pre-pregnancy BMI,5,23 and also that 
metabolic status during these periods could be involved in mammary gland development and 
lactogenesis I and II.24 This is important because GWG, PPWL, and subclinical glucose 
dysregulation may be more easily modifiable aspects of maternal metabolic status than are 
current or pre-pregnancy BMI.
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The present study aimed to test the relationship of maternal pre-pregnancy BMI, gestational 
weight gain (GWG), postpartum weight loss (PPWL), and oral glucose tolerance test 
(OGCT) results with breastmilk hormone concentrations (leptin, insulin, and adiponectin). 
We hypothesized that greater pre-pregnancy BMI, excessive GWG, higher OGCT, and lower 
PPWL would be associated with higher concentrations of insulin and leptin, and lower 
concentration of adiponectin in breastmilk, and that these associations would vary from 
earlier in lactation (1 month) to later in lactation (3 months).
Methods
Study Sample
The present analysis used data from the Mothers and Infants Linked for Healthy Growth 
(MILk) study. The MILk study is a prospective cohort study taking place at the University of 
Oklahoma Health Sciences Center and University of Minnesota, in collaboration with 
HealthPartners Research Foundation in Minnesota. This study was approved by the 
Institutional Review Boards of University of Minnesota, University of Oklahoma Health 
Sciences Center, and HealthPartners Institute for Education and Research. Informed consent 
was obtained from all adult participants. The MILk study is registered with clinicaltrials.gov 
(NCT03301753).
At enrollment, study participants were 1) women in their second trimester of a singleton 
pregnancy; 2) 21 to 45 years old at time of delivery; 3) 18.5-40 kg/m2 BMI at first prenatal 
visit; and 4) self-reported to have social support for and intention to exclusively breastfeed 
for at least three months. Women were excluded if they had 1) alcohol consumption of 2 or 
more drinks per week during pregnancy and lactation; 2) tobacco use during pregnancy and 
lactation; 3) history of or current Type I, II, or gestational diabetes; 4) unable to speak or 
understand English; and 5) presence of a known infant congenital metabolic or endocrine 
disease, or other congenital illness affecting the infant’s feeding/growth. Of these enrolled 
women, those who delivered a term infant (37-42 weeks’ gestation) with a birth weight 
≥2,500 g and ≤ 4,500 g) and who were exclusively breastfeeding at 1-month post-partum 
were requested to provide milk samples at the study center.
A flow diagram of MILk study participants included in this analysis is found in 
Supplemental Figure 1. At the time of this analysis, a total of 253 pregnant women had been 
enrolled in the study and had given birth to an infant, who was at least 3 months old, of 
whom 170 met all of the criteria for continuation in the post-partum phase of the study. Of 
these, 153 women provided 1 and 3 months milk samples, and 135 of these had sufficient 
milk for all measurements (>=25 ml) and their samples were sent to the laboratory for assay. 
After removing statistical outliers and missing covariate information, data were available for 
130 women in the pre-pregnancy BMI and GWG analyses, and 129 women in the OGCT 
and postpartum weight loss analyses. To assess potential bias, these groups of participants 
were compared; differences in the means of important participant characteristics were tested 
using the Student’s T-test and differences in frequency of categorical variables were tested 
using Fischer’s Exact Test. Maternal BMI (26.1 vs. 28.2, P=0.0042) and infant birth weight 
(3541 vs. 3325 g, P=0.0118), but not maternal age differed between women that were 
eligible to participate in post-partum milk collection (N=170) as compared to women who 
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were excluded, respectively. There were also significant differences using Fisher’s Exact 
Test in maternal race (P=0.0014), maternal ethnicity (P=0.0081), and type of insurance 
(P=0.0070), but not infant sex (P=0.12) or delivery mode (P=0.11).
Maternal Characteristics
Pregnancy history data were collected from the electronic health records, including 1) 
maternal and gestational age at time of delivery; 2) first recorded maternal weight and height 
in the medical record within 6 weeks from conception (dated using last menstrual period), 
which was used to calculate pre-pregnancy BMI; 3) GWG calculated as body weight at 
admission for delivery minus the first recorded maternal weight as above; 4) mode of 
delivery coded as caesarean section or vaginal delivery; and 5) parity as number of times a 
woman has given birth to an infant over 24 weeks of gestational age. Subclinical glucose 
dysregulation was captured by the 1-hour blood glucose concentration after a 50g oral 
glucose challenge test (OGCT), administered between 26-28 weeks of gestation to screen for 
gestational diabetes (GDM). Women with OGCT levels greater than 140 g/dl received an 
oral glucose tolerance test to confirm and exclude those with GDM. Postpartum weight loss 
was calculated as the difference between maternal delivery weight and her body weight 
measured at the 1- and 3 months post-partum visits.
Human milk collection
Mothers and infants were scheduled and seen at the study centers within 5 days of the 1-
month and 3-month time points, between 8:00-10:00 am. The mother was instructed to be 
ready to breastfeed the infant upon arrival, and then fed the child ad libitum from one or 
both breasts as per her usual practice and whether the infant was fed from the left, right, or 
both breasts was recorded. Two hours after feeding, the mother provided a single complete 
breast expression sample (until the flow of milk stopped) from the right breast using a 
hospital-grade electric breast pump (Medela Symphony; Medela, Inc. Zug, Switzerland) 
ensuring the collection of fore-, mid- and hind-milk within each sample.12,25 The volume 
and weight of the milk collected from the single breast expression were recorded. Breast 
milk was gently mixed, aliquoted, and stored at −80°C within 20 minutes of collection.
Milk Hormone Assays
Skimmed milk samples were prepared, stored at −80° C for up to 6 months. Leptin, insulin, 
total adiponectin was assayed using commercially available ELISA kits as previously 
described by Fields et al.12 and in Supplemental File 1. The inter- and intra-assay 
coefficients of reliability were <6% for all hormones and limits of quantitation were 0.24 
µU/ml for insulin, 1 ng/ml for total adiponectin, and 7.86 pg/ml for leptin.
Statistical Analysis
Data were analyzed using SAS 9.4 (Cary, NC, USA.). Dependent variables were examined 
using histograms and quantile-quantile (Q-Q) plots to determine normality. Milk leptin, 
adiponectin and insulin concentrations were positively skewed and were log transformed for 
all subsequent analyses.
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Descriptive statistics were presented by pre-pregnancy BMI group (normal weight, 
overweight, and obese), with chi-square tests and one-way ANOVA applied to identify 
potential confounding variables for the primary exposure, maternal BMI. Differences in milk 
hormone concentrations from 1- to 3 months were tested using paired t-tests.
Separate mixed effects linear regression models were used to test the association of maternal 
pre-pregnancy BMI, and each of the other maternal metabolic factors, with each repeated 
milk hormone measure (leptin, insulin, adiponectin). Preliminary analyses by pre-pregnancy 
BMI category and tertiles of OGCT, GWG, and PPWL showed a stepwise, dose-response 
relationship with milk hormones across groups for BMI, OGCT, and PPWL, suggesting 
linearity, but non-linear associations were observed for GWG. Pre-pregnancy BMI, OGCT 
glucose concentration, and PPWL were therefore treated as continuous variables, while 
GWG was dichotomized as below/within versus above the Institute of Medicine (IOM) 2009 
guidelines.26 The compound symmetry covariance structure for the repeated measures was 
selected as best by comparing AIC across models. Crude models included only the main 
effect of the metabolic factor, time (1- and 3 months) and their interaction. Adjusted models 
additionally included variables that differed across maternal BMI categories (p<0.15) or 
were identified from the literature to be associated with milk composition. These included 
maternal age, parity, education level, gestational age at birth, infant sex, mode of delivery 
(vaginal or cesarean section), exclusive breast milk feeding at 3 months (yes/no), and breast 
milk volume. Adjusted regression models testing GWG, OGCT, and PPWL also included 
pre-pregnancy BMI as a covariate. Significance was set at α=0.05. Sensitivity analyses 
examined the influence of the following on regression estimates of the exposure variables: 
infant birth weight z score, which breast (right or left) was used during the test feeding, 
restriction of the analysis to exclusively breast feeding dyads at 3 months, removal of three 
women with GWG below IOM guidelines, and reduction of covariates to those with p<0.15 
in bivariate analysis.
Results
Baseline characteristics
Descriptive statistics stratified by pre-pregnancy BMI groups are shown in Table 1. Attained 
education level, gestational age of the infant at birth, the frequency of excessive GWG, and 
PPWL at 3 months were significantly different between normal weight, overweight, and 
obese women in the sample (p<0.05). All the women were exclusively breastfeeding at 1- 
month by design, and 93% were still exclusively breastfeeding at 3 months. This tended to 
be slightly lower in women with pre-pregnancy obesity and overweight than in women in the 
pre-pregnancy normal weight category.
Hormone Concentrations from 1- to 3 Months Postpartum
Mean concentrations of the breastmilk hormones (raw and log transformed) at 1- and 3 
months are reported in Table 2. Mean log transformed adiponectin and leptin significantly 
decreased (p-value = 0.0006 and < 0.0001, respectively) from 1- to 3 months with no such 
change observed in insulin. The serial measures of milk leptin and insulin were highly 
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correlated from 1- to 3 months (r = 0.75 and 0.70, respectively; p-value < 0.0001), but no 
serial correlation was observed for adiponectin (r = 0.07; p-value = 0.41).
Hormone Concentrations and Relationships to Maternal Metabolic Characteristics
Table 3 provides results from the unadjusted and adjusted models assessing the association 
of maternal metabolic characteristics with milk leptin concentrations. There was a positive 
association between pre-pregnancy BMI and leptin in both the crude and adjusted models (β 
= 0.525 and 0.494 respectively, p-value < 0.001). In addition, there was a statistically 
significant, independent, difference between GWG (below/within vs. exceed guidelines) and 
leptin levels (crude: β =0.488 p-value = 0.0001; adjusted: β= 0.298 p-value = 0.009). PPWL 
was inversely associated with leptin concentration in the crude model, and remained 
significant in the adjusted models (β = −0.235 p-value = 0.001, β = −0.184 p-value =0.003 
respectively). OGCT results at 1- and 3 months were not associated with breastmilk leptin in 
any of the tested models. The exposure-time interaction was not significant in any of the 
tested leptin models.
As seen in Table 4 pre-pregnancy BMI was inversely associated with milk adiponectin in the 
crude model (β= −0.067, p-value = 0.02) and remained significant in the adjusted model (β= 
−0.070, p-value = 0.02). The pre-pregnancy BMI- time interaction was statistically 
significant (p-value = 0.001 and p-value = 0.045 in crude and adjusted models, respectively), 
indicating that the association between maternal BMI and adiponectin was different at 3-
months as compared to 1 month (referent). The positive beta coefficient for the interaction 
term indicates that the negative main effect of maternal pre-pregnancy BMI with adiponectin 
was weaker (closer to zero) at 3 months as compared to 1 month. The other three maternal 
metabolic characteristics were not associated with milk adiponectin concentration.
For the insulin models shown in Table 5, a positive association between pre-pregnancy BMI 
and insulin was observed in both the crude and adjusted models (β= 0.177, p-value = 0.003; 
and β= 0.144, p-value = 0.030, respectively). In addition, the pre-pregnancy BMI-time 
interaction was statistically significant (p-value = 0.002 and p-value = 0.017) marking a 
difference in the association at 1 and 3 months. Here, the positive beta coefficient for the 
interaction term indicates that the positive main effect of maternal pre-pregnancy BMI on 
milk insulin was stronger (more positive) at 3 months as compared to 1 month. No other 
significant associations were observed between maternal factors and milk insulin 
concentration levels.
Given that only education and gestational age at birth were statistically significant in the 
mixed effect models, more parsimonious mixed effect linear regression models adjusting for 
education and gestational age only were performed. These models resulted in very similar 
findings, and therefore, these results were not reported. In additional analyses, we found no 
significant association of birth weight z score, or which breast the infant fed from during the 
test feed, on any of the outcomes (p>0.15) and the estimates of BMI, GWG, PPWL, and 
OGCT were not influenced significantly (greater than 10% difference in regression 
coefficient) by their inclusion (results not shown). Restriction to dyads that were exclusively 
breast feeding at 3 months or who had GWG greater than or equal to IOM guidelines 
likewise did not alter the results.
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Discussion
In this longitudinal analysis from birth to 3 months postpartum, maternal pre-pregnancy 
BMI was positively associated with elevated concentrations of leptin and insulin and lower 
concentrations of adiponectin in mature human milk, after adjusting for potential 
confounders. In addition, we found a statistically higher milk leptin concentration in women 
whose GWG exceeded the IOM guidelines as compared to those whose GWG was either 
below or within the IOM guidelines, independent of time. Lastly, our study has shown a 
negative association between postpartum weight loss and concentration of milk leptin level, 
independent of time. Our findings on the association of pre-pregnancy BMI and increased 
leptin levels is largely consistent with other studies; however, our findings on the time-
dependent relationship of pre-pregnancy BMI and higher concentration of milk insulin and 
lower concentration of milk adiponectin, as well as the relationships of excessive GWG and 
lower postpartum weight loss with milk leptin, are novel to the field.
Leptin is an appetite-regulating hormone produced in the adipose tissue,27 as well as 
epithelial cells of the mammary gland,28 and has been found in much higher concentrations 
in human serum compared to breastmilk,20 and in serum of obese than normal weight 
women.29 Milk leptin’s positive association with maternal BMI (with a small number of 
exceptions19,30) has been well established.11,13,16,31 Our results confirmed this association 
in exclusively breastfeeding women and extended it by documenting that milk leptin 
concentration is responsive to dynamic aspects of weight change in pregnancy and lactation. 
Maternal serum leptin increases during late gestation and declines after parturition (the so-
called “leptin surge”), which phenomenon is thought to be critical for maturation of appetite 
regulating centers in the fetal brain,32 and which we saw reflected in a significant decline in 
milk leptin from 1 to 3 months. Milk leptin is thought to derive in large part from maternal 
serum, the level of which tracks changes in adiposity; this may explain why we found it to 
associate with maternal GWG and PPWL as well as BMI. It is not clear why the same 
results were not found for insulin or adiponectin, but it may relate to differences across 
hormones in the degree to which their appearance in milk occurs via active expression 
and/or transport by the mammary epithelial cells rather than passive paracellular diffusion.
21,32
 Serial measurement of maternal serum would help to address this point in future. 
Randomized weight management trials during these critical periods could also better assess 
whether the relationships we have observed are causal.
Secreted by adipose tissue, serum adiponectin is inversely associated with adiposity, plays a 
role in modulation of glucose and lipid metabolism in insulin sensitive tissues, and has anti-
atherogenic and anti-inflammatory effects.17,33–35 Adiponectin is one of the most abundant 
milk hormones, the concentration of which is thought to be driven by maternal circulating 
levels. Milk levels decline over the period of lactation36, as we have also shown here from 1 
to 3 months. We found a time dependent inverse relationship between maternal pre-
pregnancy BMI and milk adiponectin, with a stronger (negative) association observed at 1-
month than at 3 months post-partum. Literature to date is inconsistent on the association of 
maternal BMI and milk adiponectin,14,16–19 with no clear association between maternal 
BMI and adiponectin levels in colostrum, hindmilk, foremilk, or whole milk. Martin et al.18 
first showed a positive association of maternal BMI with adiponectin concentrations in 
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breastmilk in a study of 22 women with serial skimmed milk samples, but this finding was 
based on post-pregnancy, and not pre-pregnancy BMI, and was not confirmed after covariate 
adjustments. Other studies that reported no association between maternal BMI and milk 
adiponectin levels had lower precision of estimates due to fewer women with elevated BMI, 
self-reported maternal weights, and wide infant age ranges for milk sampling.14,17,18 Our 
results of a diminished association over time supports findings by Chan et al.16 who reported 
no association between maternal pre-pregnancy BMI and adiponectin levels in breastmilk at 
3 to 4 months postpartum. The finding points out the importance of timing of milk 
collection. The relative benefits of hormones in early versus later milk for infant growth 
remain to be determined.
Produced in the pancreas, insulin plays a major role in maintaining glucose homeostasis and 
metabolic function, but also has less recognized roles in appetite suppression through 
receptors binding in hypothalamic neurons,37,38 and as a potent growth regulating hormone 
in early life.39 Milk insulin concentration is found at equimolar concentrations as in 
maternal serum and is thought to be actively transported into milk by the mammary 
epithelial cell, rather than diffusing through the paracellular pathway.21 This active transport 
may explain why we found that milk insulin did not decline on average from 1 to 3 months 
post-partum, in contrast to leptin and adiponectin. Indeed, the positive association between 
maternal pre-pregnancy BMI and milk insulin not only remained significant from 1- to 3 
months but was stronger at the later time point. Previous findings on the relationship of 
maternal BMI to milk insulin have been mixed. Our results are consistent with several other 
studies reporting a positive correlation with maternal pregnancy BMI.21,22 In contrast, 
Shehadeh et al.15 reported post-partum maternal BMI (measured at the time of breastmilk 
sample collection), to have no influence on insulin concentrations in transitional milk (days 
3 and 10). Two other studies, which may have suffered from low statistical power due to low 
sample size14,16 also showed no association between pre-pregnancy BMI and milk insulin 
levels. These results warrant further investigation on the potential role of milk insulin in 
infant appetite, metabolic rate and obesity risk.
Strengths and Limitations
This study had a rigorous milk collection protocol, where all the samples were expressed 
with the same equipment, collected in the morning and precisely two hours after the 
previous breast feeding, and within narrow age-specific collection windows. This allowed 
for control of diurnal and lactation stage variations in milk which have been well recorded.40 
Numerous confounding and technical factors were assessed, and our sample included a 
relatively large proportion of overweight and obese women. There were also some 
limitations to this study. First, whether maternal weight changes relate specifically to milk 
hormone levels in foremilk versus hind milk was not assessed,11. Second, study population 
was relatively homogenous in ethnic and racial composition, making the results less 
generalizable to non-White or Hispanic populations. Third, the effect sizes for the 
relationship of milk hormones with GWG, PPWL, and OGCT appear to be weaker than for 
pre-pregnancy BMI; our finding that GWG and PPWL had relationships only with leptin 
level may be a function of statistical power. Fourth, potential confounding effects of 
maternal physical activity level and dietary intake were unavailable for analysis. Finally, lack 
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of maternal serum hormone concentrations limited the ability to explain observed 
differences in results across the different milk hormones.
Conclusions
Numerous benefits of breastfeeding to the health of the infant and the mother have been 
established,1,2 however much is to be learned regarding the causes and consequences of 
individual variation in breastmilk composition. Our study advances this body of knowledge 
by 1) showing that milk hormone concentrations and their relationship with maternal 
metabolic status change over time, and 2) illustrating that not only pre-pregnancy BMI but 
also gestational weight gain and postpartum weight loss are associated with variation in milk 
leptin. Future work will test the relationship of these and other milk bioactive components 
with infant growth and metabolic health.
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What is Already Known About This Topic
• Human milk is a highly complex fluid and varies between and within women 
over time, but the determinants of this variation remain understudied.
• Human milk leptin concentration increases in a stepwise fashion with 
increasing maternal BMI.
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What This Study Adds
• Concentrations of leptin and adiponectin in mature human milk decline from 
1 to 3 months, while milk insulin does not change over this period of 
lactation.
• Milk leptin increases with greater gestational weight gain and lower post-
partum weight loss, independent of its relationship with pre-pregnancy BMI
• Pre-pregnancy BMI is positively associated with milk insulin and negatively 
associated with milk adiponectin, and the strength of these relationships 
change from 1 to 3 months post-partum.
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